The following is from Children’s Health Defense.
Two Children’s Health Defense (CHD) scientists have published a research letter titled “Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine in the United States” in Science, Public Health Policy and the Law. The research focuses on specific batches of Pfizer’s COVID-19 vaccine, referred to as “hot lots,” which are linked to higher rates of adverse events or injuries compared to other batches.
This new research builds on earlier findings from Denmark, which identified unexpected batch-dependent suspected adverse events (SAEs) following Pfizer-BioNTech’s COVID-19 vaccination. The Denmark study found that larger vaccine lot sizes were linked to lower SAE rates.
CHD’s Chief Scientific Officer Brian Hooker, Ph.D., and Senior Research Scientist Karl Jablonowski compared the Denmark results with data in the United States to identify similar patterns within the larger US population. They used Pfizer vaccine dose data and SAE case data from the Vaccine Adverse Event Reporting System (VAERS) to identify associations between vaccine doses and SAEs.
The researchers obtained Pfizer vaccine lot data through a Freedom of Information Act (FOIA) request by the Informed Consent Action Network in October 2022. They tracked vaccine batches from manufacturing sites to distribution centers. The research indicated that earlier batches sent to large distribution centers like hospitals had more side effects than later batches sent to pharmacies and grocery chains. Some of these early lots were associated with higher rates of deaths and serious adverse events.
Interestingly, while a high number of deaths were expected in states with larger populations, such as California, Texas, and New York, the researchers found that the proportion of serious injuries and deaths was relatively higher in states like South Dakota, Kentucky, and Tennessee.
“These unexpected, widely divergent adverse event reports highlight the extreme lot-to-lot variability in the Pfizer BioNTech vaccine, illustrating myriad problems associated with the manufacture of these products.
This rushed, ‘warp speed’ production process should have never been approved in the first place.”Brian Hooker, Ph.D., Chief Scientific Officer, CHD
Read the full research letter here.
For more information or to donate to CHD, visit ChildrensHealthDefense.org.
NOW AVAILABLE: FOLLOW THE $CIENCE
Order Sharyl Attkisson’s New Bestseller!
Pfizer targeted Red states with bad batches? Could that be.